Discovery of Eriodictyol as Putative Exportin-1 Inhibitor for Non-small Cell Lung Cancer Therapy

Exportin-1, the ubiquitous nuclear protein transporter, is widely confirmed as an active chemotherapeutic target in non-small cell lung cancer conditions, while Juglans mandshurica is a well-studied anticancer plant in some lung cancer cell lines. We intend to find a novel exportin-1 inhibitor from Juglans mandshurica with better potential, tolerability and pharmaco-dynamo-kinetic properties than the current selective inhibitors of nuclear export in non-small cell lung cancer treatment. OSIRIS DataWarrior, along with Glide standard precision docking, and other Glide modules were employed for compound properties exploration, docking simulations, free energy calculations against exportin-1; density functional theory analysis of the compounds were carried out to estimate their electronic stability, while web-based SWISSADME was employed for ADMET and synthetic accessibility evaluations. This study reveals eriodictyol as having higher binding free energy (-40 kcal/mol) than that of standard (-39.56 kcal/mol) in exportin-1 active site, better synthetic accessibility score (3.15 versus 3.29), high GI absorption, non-blood brain barrier permeant, lacks Brenk and PAINS alert, obeying Lipinski’s, Ghose’s, Veber’s, Egan’s, and Muegge’s rule of drug-likeness and lead-likeness as well as non-cytotoxic to HepG2 cells. We therefore found eriodictyol as a lead-like, non-toxic exportin-1 inhibitor with good predictive stability and pharmacokinetic potential and thus provided data for further validation of eriodictyol as a candidate exportin-1 inhibitor in both preclinical and clinical studies involving lung cancer therapy.

Year Of Publication
Page Range
Issue Number

Evaluation of the Antimicrobial, Antioxidant and the Staining Property of Cnestis ferruginea Ethanoic Fruit Extract

Nkechi Augustina Olise, Ifeoma Bessie Enweani-Nwokelo